BIOVF News and Press, Swedish Orphan Biovit Ord From 10/31/19

STOCKHOLM , Oct. 31, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2019. Revenue growth in the quarter was 27 per cent with revenue of SEK 2,930 M (2,315). EBITA was SEK 1,099 M , resulting in an EBITA margin ...

STOCKHOLM , Oct. 23, 2019 /PRNewswire/ -- On 31 October, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presenta...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...

Dova Pharmaceuticals (NASDAQ: DOVA ) is up  38%  premarket after entering into an agreement and plan of merger with Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) (Sobi). More news on: Dova Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Stocks o...

STOCKHOLM , Sept. 30, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 p...

Endo International (NASDAQ: ENDP ) is up  3%  premarket on light volume in reaction to the FDA nod for subsidiary Endo Ventures partner's Novitium Pharma's generic version of Swedish Orphan Biovitrum's ( OTCPK:BIOVF ) Orafin (nitisinone capsules) for the treatment of hereditary t...

The FDA has signed off on Seelos Therapeutics' ( SEEL +7.3% ) IND for a Phase 2b/3 clinical trial evaluating SLS-005 (trehalose) in patients with mucopolysaccharidosis type III (Sanfilippo syndrome), an inherited disorder characterized by delayed speech and behavioral problems that is ...

Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) has entered into an agreement to sell a FDA Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of $95M. More news on: Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Read more ...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2019 Earnings Conference Call July 17, 2019 03:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Milan Zdravkovic - Head of Research & Development and Chief Medical Of...